Document Type

Article

Publication Date

4-1-2013

Comments

This article has been peer reviewed. It was published in: Oncoimmunology.

2013 April 1; 2(4): e23660. .

The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654591/. DOI: 10.4161/onci.23660

Copyright © 2013 Landes Bioscience

Abstract

Recently, we have shown that the CCL5/CCR5 axis is active in patients affected by an aggressive basal subtype of breast cancer. Using preclinical models, we have demonstrated that CCR5 promotes breast cancer invasiveness and metastatic potential, while CCR5 inhibition abrogates them. Thus, CCR5 antagonists may constitute an alternative therapeutic approach for patients affected by metastatic basal breast cancer.

Included in

Oncology Commons

Share

COinS